These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30937437)

  • 1. Fractional-dose yellow fever vaccination: an expert review.
    Roukens AHE; Visser LG
    J Travel Med; 2019 Sep; 26(6):. PubMed ID: 30937437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
    Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Kimathi D; Juan-Giner A; Orindi B; Grantz KH; Bob NS; Cheruiyot S; Hamaluba M; Kamau N; Fall G; Dia M; Mosobo M; Moki F; Kiogora K; Chirro O; Thiong'o A; Mwendwa J; Guantai A; Karanja HK; Gitonga J; Mugo D; Ramko K; Faye O; Sanders EJ; Grais RF; Bejon P; Warimwe GM
    Lancet Infect Dis; 2023 Aug; 23(8):974-982. PubMed ID: 37127045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Juan-Giner A; Namulwana ML; Kimathi D; Grantz KH; Fall G; Dia M; Bob NS; Sall AA; Nerima C; Sahani MK; Mulogo EM; Ampeire I; Hombach J; Nanjebe D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet Infect Dis; 2023 Aug; 23(8):965-973. PubMed ID: 37127047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis.
    Nnaji CA; Shey MS; Adetokunboh OO; Wiysonge CS
    Vaccine; 2020 Feb; 38(6):1291-1301. PubMed ID: 31859201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
    Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
    N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study.
    Doshi RH; Mukadi PK; Casey RM; Kizito GM; Gao H; Nguete U B; Laven J; Sabi L; Kaba DK; Muyembe-Tamfum JJ; Hyde TB; Ahuka-Mundeke S; Staples JE
    Lancet Infect Dis; 2024 Jun; 24(6):611-618. PubMed ID: 38335976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractional dosing of yellow fever vaccine to extend supply: a modelling study.
    Wu JT; Peak CM; Leung GM; Lipsitch M
    Lancet; 2016 Dec; 388(10062):2904-2911. PubMed ID: 27837923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractional-dose yellow fever vaccination: how much more can we do with less?
    Visser LG
    Curr Opin Infect Dis; 2019 Oct; 32(5):390-393. PubMed ID: 31335440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
    Roukens AHE; van Halem K; de Visser AW; Visser LG
    Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
    Barrett ADT
    Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
    Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
    Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractional-Dose Yellow Fever Vaccination - Advancing the Evidence Base.
    Vannice K; Wilder-Smith A; Hombach J
    N Engl J Med; 2018 Aug; 379(7):603-605. PubMed ID: 29995585
    [No Abstract]   [Full Text] [Related]  

  • 15. Single shot of 17D vaccine may not confer life-long protection against yellow fever.
    Vasconcelos PF
    Mem Inst Oswaldo Cruz; 2018 Feb; 113(2):135-137. PubMed ID: 29185596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.
    Roukens AH; Vossen AC; Bredenbeek PJ; van Dissel JT; Visser LG
    PLoS One; 2008 Apr; 3(4):e1993. PubMed ID: 18431480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines.
    Juan-Giner A; Warimwe G
    Lancet Infect Dis; 2024 Jun; 24(6):562-564. PubMed ID: 38335975
    [No Abstract]   [Full Text] [Related]  

  • 20. Yellow fever vaccine: an effective vaccine for travelers.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.